Keybanc analyst John Vinh maintains Broadcom (NASDAQ:AVGO) with a Overweight and lowers the price target from $780 to $700.
Reported Late Monday, Kazia Therapeutics Announces Research Collaboration With QIMR Berghofer Medical Research Institute To Investigate The Utility Of Its Lead Asset, Paxalisib In Solid Tumors
Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR
